A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

• Has had a diagnosis of CD at least 3 months before study.

• Has moderately to severely active CD.

• Demonstrated inadequate response, loss of response, or intolerance to one or more ofthe following categories of drugs: oral locally acting steroids, systemic steroids,immunomodulators, biologic and/or small molecule advanced therapies.

• Adolescent participants ≥16 and <18 years of age can participate if approved by thecountry or regulatory/health authority.

Exclusion Criteria:

• Has diagnosis of ulcerative colitis (UC) or indeterminate colitis.

• Has CD isolated to the stomach, duodenum, jejunum, or perianal region, withoutcolonic and/or ileal involvement.

• Currently has any of the following complications of CD: suspected or diagnosed withintra-abdominal or perianal abscess, known symptomatic stricture or colonic stenosisnot passable in endoscopy, fulminant colitis, toxic megacolon, or any othermanifestation that might require surgery while enrolled in the study.

• Has current stoma or need for colostomy or ileostomy.

• Is missing >2 segments of the following 5 segments: terminal ileum, right colon,transverse colon, sigmoid and left colon, and rectum.

• Has been diagnosed with short gut or short bowel syndrome, or any other uncontrolledchronic diarrhea besides Crohn's disease.

• Has surgical bowel resection within 3 months of study.

• Has prior or current gastrointestinal dysplasia.

• Has chronic infection requiring ongoing antimicrobial treatment.

• Has a history of cancer (except fully treated non-melanoma skin cell cancers orcervical carcinoma in situ after complete surgical removal) and is disease free for <5 years.

• Is infected with Hepatitis B virus (HBV), Hepatitis C virus (HCV), or humanimmunodeficiency virus (HIV).

• Has active tuberculosis.

• Has confirmed or suspected coronavirus disease of 2019 (COVID-19) infection.

• Prior exposure to tulisokibart (MK-7240, PRA023) or another anti-TL1A antibody.